capsid engineering

AAVion is a biotechnology company developing next-generation AAV gene therapies to overcome the limitations of conventional gene delivery and expand access to genetic medicines. Its proprietary platform enables delivery and restoration of therapeutic genes that exceed the traditional AAV packaging limit. AAVion is advancing gene therapies for rare inherited cardiomyopathies and neuromuscular disorders. It was founded by Dr. Prasad Konkalmatt, an AAV gene therapy scientist.

AAV gene therapy developmentDual-AAV strategy for large gene deliverypreclinical testingpromoter engineeringvector design

Affinia Therapeutics is a gene therapy company developing adeno-associated virus (AAV) gene therapies for rare and prevalent diseases, starting with diseases of the heart and nervous system. Its proprietary ART (Affinia Rationally-designed Therapies) platform uses AI and structural modeling to rationally design novel AAV capsids and therapeutic payloads. Its first program, AFTX-201, targets BAG3-associated dilated cardiomyopathy (DCM).

AAV-gene therapyAI and structural modelinggene editinggene replacementgene therapy manufacturingknockdownpayload designvectorized antibody

Divergene is a technology company providing AI-driven analytics and informatics for cell & gene therapy and bioprocessing. It offers a bioinformatics platform and AI framework for next-generation sequencing analysis, vector engineering, and vector quality control, and provides AI-driven digital-twin simulation of bioreactors and bioprocesses. The team includes Ph.D.-level bioinformaticians, data scientists, and AI experts.

AI-driven digital-twin simulationBioinformaticsbioprocess modelinglibrary preparationnext-generation sequencingQCsequencing analysisvector engineeringvector quality control